Doctor of Philosophy by Park, Songyoung
THE INTEGRATED FUNCTION OF CARDIAC, SKELETAL, AND VASCULAR 
SMOOTH MUSCLE: LIMITATIONS TO OXYGEN TRANSPORT AND  














A dissertation submitted to the faculty of 
The University of Utah 
















Department of Exercise and Sport Science 












Copyright © Songyoung Park 2015 













The dissertation of Songyoung Park 
has been approved by the following supervisory committee members: 
 
Russell S. Richardson , Chair 6/18/2015 
 
Date Approved 
J. David Symons , Member 6/18/2015 
 
Date Approved 
D. Walter Wray , Member 6/18/2015 
 
Date Approved 
Stavros G. Drakos , Member 6/18/2015 
 
Date Approved 




and by Janet M. Shaw , Chair/Dean of  
the Department/College/School of Exercise and Sport Science 
 







The purpose of this dissertation was to investigate the integration of cardiac, 
skeletal, and vascular smooth muscle in the process of oxygen (O2) transport and 
utilization. The goal of the first study was to examine the vasomotor function of human 
skeletal muscle feed arteries (SMFAs), utilizing pressure myography, with a focus on the 
impact of age. In this study, we demonstrated that in response to an increased shear stress, 
the SMFAs likely contribute to the regulation of vascular resistance/conductance in vivo. 
Furthermore, aging likely blunts the capacity to delivery O2 due to reduced endothelial 
function in these SMFAs identified by attenuated kinetics of vasodilation and maximum 
vasodilatory capacity. Additionally, this attenuated vascular function was associated with 
a reduction in the shear-induced activation of eNOS, and elevated free radical production 
in SMFAs with age. The second study using normal healthy donor hearts (HdH) as a 
reference, sought to examine the impact of heart failure (HF) etiology on mitochondrial 
function in the pathology. Specifically, this study examined cardiac muscle mitochondrial 
function and free radical production in patients with ischemic HF (iHF) in comparison to 
that of patients with non-ischemic HF (niHF). Both mitochondrial quality and quantity 
were compromised in HF compared to HdH. Interestingly, a lower tissue mass specific 
oxidative phosphorylation (OXPHOS) capacity was documented in iHF compared to 
niHF, which was predominantly due to reduced mitochondrial content. However, 
increased non-phosphorylating respiration, and elevated mitochondrial derived free  
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radical production, as well as an attenuated efficiency of OXPHOS in iHF compared to 
niHF suggests an etiology-specific reduction in intrinsic mitochondrial function in iHF. 
However, increased non-phosphorylating respiration, and elevated mitochondrial-derived 
free radical production, as well as an attenuated efficiency of OXPHOS in iHF compared 
to niHF, suggests an etiology specific reduction in intrinsic mitochondrial function in iHF. 
Therefore, this study identified HF etiology as an important contributor to the functional 
abnormalities associated with HF. The third study examined the characteristics and 
respiratory function of mitochondria in cardiac, skeletal, and vascular smooth muscle. 
Tissue-specific mitochondrial OXPHOS normalized by citrate synthase activity (CSA) 
was similar in cardiac, skeletal, and smooth muscle; however, there were significant 
muscle-specific differences in both non-phosphorylating respiration and efficiency of 
OXPHOS. These findings suggest that different muscle tissues have distinct intrinsic 
mitochondrial function which may influence the efficiency of OXPHOS and potentially 
free radical production. In summary, this set of studies has identified novel mechanisms 
underlying blunted O2 supply and utilization often associated with aging and disease in 
humans. 
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The oxygen (O2) cascade, a stepwise movement of O2 from atmospheric air to the 
mitochondria of muscle and other organs, starts in the lung where O2 is transferred from 
air to blood. The O2 rich blood is then propelled by the rhythmic pumping of the heart 
through blood vessels, steered by changes in vascular resistance to deliver O2 to 
metabolically active tissue [1, 2]. Thus, especially during physical activity, the 
cardiovascular system, including the heart and blood vessels, work in concert to transfer 
O2 rich blood to skeletal muscle, where the mitochondria consume O2 to produce energy 
in the form of adenosine triphosphate (ATP) by oxidative phosphorylation (OXPHOS). 
Therefore, cardiac muscle, the vascular smooth muscle, skeletal muscle, and the 
integration of these three muscle systems, are major components of the O2 transport and 
utilization systems [1]. 
 Although the O2 cascade has been studied in earnest for many decades, numerous 
mechanisms and the implications of alterations in function due to aging and disease, such 
as attenuated convective O2 transport capacity and apparent mitochondrial dysfunction, 
remain poorly understood. Therefore, the purpose of this dissertation was to investigate 
three topics related to O2 transport and utilization linked by the integrative function of the 
heart, skeletal, and smooth muscle in health and disease. Specifically, the first study 
focused upon how aging impacts the vasodilatory capacity of human skeletal muscle feed 
arteries (SMFA). The second study examined the impact of heart failure (HF) and more 
specifically the effect of HF etiology on mitochondrial function in cardiac muscle. 
Finally, the third study comprehensively assessed and compared mitochondrial 
respiratory function in cardiac, skeletal, and, for the first time, smooth muscle. Therefore, 
by examining components of these three muscle systems, the overarching goal of this 
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dissertation was to contribute significantly to our understanding of the limitations to O2 
transport and utilization in health and disease. 
 
 
Blood flow regulation in the peripheral vasculature and the impact of age 
 
In addition to the significant role that the heart plays in the convective delivery of 
O2, predominantly the maintenance of blood pressure, the vasomotor function of blood 
vessels, which regulates resistance, is the major determinant of blood flow distribution. 
Indeed, blood vessels act as an important “middle man” in the transfer of oxygenated 
blood from the heart to areas of high O2 demand, such as skeletal muscle [2]. Therefore, 
especially during exercise, optimal vasodilatory function of blood vessels is essential to 
meet skeletal muscle O2 demand [2]. These convective components of cardiovascular O2 
delivery system, the heart and blood vessels, can be regulated by many factors, including 
neural, hormonal, and local mechanisms [1]. At the onset of exercise, neural control is 
often considered the primary blood flow regulator, then hormonal regulation and local 
control predominate. However, these mechanisms work both independently and 
interactively in response to significantly increased O2 demand in the transition from 
resting to working skeletal muscle [3]. Interestingly, previous studies suggested that the 
impairment of local vasodilatory mechanisms at the onset of exercise may play a critical 
role in limiting O2 transport and therefore exercise capacity in both healthy aging and 
disease [4-6]. 
The impaired local vasodilatory mechanisms, as exemplified by diminished 
vascular function with age, cause a temporal O2 delivery to O2 demand mismatch across 
the rest to exercise transition, which has been documented in both animals and humans [7, 
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8]. There are several mechanisms responsible for this age-related reduction in O2 delivery 
to skeletal muscle, including fewer SMFAs, impaired endothelium-dependent 
vasodilation mediated by reduced nitric oxide (NO) bioavailability, and alternations in 
blood vessel structure [8-11]. Although the role of arterioles in the regulation of blood 
flow distribution within skeletal muscle with age has been studied intensively [8, 9, 12], 
the regulatory function of SMFAs, directly upstream from the arterioles, and the effects 
of age on these vessels have yet to be comprehensively assessed. Therefore, the purpose 
of the first study of this dissertation was to investigate the impact of age on the 
vasodilatory capacity of SMFAs. We tested four hypotheses: First, both young and old 
SMFAs would exhibit significant vasodilatory capacity stimulated by flow-induced shear 
stress, acetylcholine (ACh), and sodium nitroprusside (SNP). Second, the endothelium-
mediated vasodilatory response (flow-induced shear stress and ACh) would be attenuated 
in the old compared to the young, whereas the endothelium-independent vasodilatory 
response (SNP) would be similar between groups. Third, the flow-induced vasodilation 
kinetics will be slowed with less activation of endothelial nitric oxide synthase (eNOS) in 
the old compared to the young. Finally, free radical levels will be greater in the old 
compared to the young.  
 
 
The impact of HF on mitochondrial respiration in cardiomyocytes 
 
Mitochondria are ubiquitous organelles constituting up to 40% of cytoplastic 
volume in mammalian tissues such as kidney, liver, and heart. Consequently, it has been 
estimated that there are upwards of 10 million billion mitochondria in a human adult [13]. 
In addition to an essential role in ATP generation, mitochondria are important 
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components of bioenergetic pathways, cellular redox homeostasis, regulation of calcium 
signaling, and apoptosis. Interestingly, as a consequence of OXPHOS, mitochondria are 
also recognized as a major source of free radicals which may result in cellular damage 
[14-18], and, thus, mitochondria have been implicated in the pathophysiology of aging 
and disease in several organs, including the brain, heart, skeletal, and smooth muscle [14, 
19, 20] . 
 OXPHOS involves the oxidation of fuels (glucose, free fatty acids, lactate, etc.) 
to make ATP which is then hydrolyzed to generate the energy which drives endergonic 
reactions essential for life. Therefore, the rate of OXPHOS and ATP hydrolysis is tightly 
matched to ATP demand and supply [21, 22]. Briefly, mitochondrial respiration involves 
the reduction of NADH and FADH2 in complex I and complex II, respectively, then these 
complexes transfer electrons to complex III through coenzyme Q. Complex IV receives 
electrons from complex III, and then reduces (consumes) O2 by adding electrons to 
produce H2O. In this electron transport process, hydrogen ions are pumped out from 
mitochondrial matrix to the intermembrane space and then, eventually, hydrogen ions are 
funneled back to the matrix though ATP synthase (complex V), providing the energy to 
produce ATP from the reaction between ADP and inorganic phosphate [22].    
Characteristics of mitochondrial function can be assessed in vitro by measuring 
tissue O2 consumption rate in a series of conditions that challenge the different 
complexes and evoke various levels of respiration. Specifically, 1) Complex I state 2 
respiration, the non-phosphorylating resting state that provides an index of proton leak, 
assessed in the presence of malate + glutamate, 2) Complex I, state 3 respiration, the 
ADP-activated state of OXPHOS, assessed in the presence of glutamate + malate + ADP, 
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3) Complex I+II, state 3 respiration, assessed in the presence of glutamate + malate + 
ADP + succinate, 4) Complex II, state 3 respiration, assessed in the presence of glutamate 
+ malate + ADP + succinate + rotenone 5) Complex IV respiration, assessed by the 
blocking of Complex 3 (antimycin A) and Complex V (oligomycin) followed by the 
addition of TMPD + ascorbate [23]. 
Utilizing these approaches, impaired skeletal muscle mitochondrial function and 
increased mitochondrial free radical production have been reported in numerous studies 
as a function of aging and disease [24-26]. However, mitochondrial function in human 
cardiac muscle is less well studied due to the limited opportunity to obtain cardiac muscle 
from healthy and diseased individuals. Furthermore, a limited number of investigations 
utilizing human heart tissue obtained from diseased hearts during routine surgeries have 
yet to clearly elucidate the impact of heart failure on mitochondrial function due to 
confounding factors such as varied etiology, severity of disease, and comorbidities. 
Mitochondria are dynamic and plastic organelles that demonstrate both structural 
and functional adaptations in response to specific stimuli, such as the increased energy 
demands associated with exercise training [27, 28]. However, alterations in 
mitochondrial function arising from changes in substrate availability and disease impair 
mitochondrial respiratory function [29-32]. Common characteristics of negatively 
impacted mitochondrial function are an impaired OXPHOS (decreased Complex I, 
Complex II, and I+II, state 3 respiration), increased O2 consumption coupled with 
decreased ATP production (increased Complex IV activity, but with lower ATP 




The heart is an organ with a high metabolic demand and is, therefore, rich in 
mitochondria, accounting for approximately 40% of cardiac tissue volume [32-35]. 
Indeed, the impressive statistics that document the human heart beating ≈100000 times a 
day and cycling through up to 30 kg of ATP in this same period (the energy required to 
climb a ≈100-story building) vividly illustrate the importance of  cardiac energy 
metabolism in both health and disease [33-36]. Specifically, as most cardiac energy 
production is derived from mitochondrial respiration, even a slight decline in 
mitochondrial function has the potential to cause significant problems in the energetic 
state of the heart [32]. In general, studies suggest that the impaired OXPHOS associated 
with HF is due to reduction in mitochondrial content, enzyme concentration, and 
enzymatic activity which are certainly important components of energy production [32, 
37]. However, impaired OXPHOS could also be a result of substrate availability, altered 
structure of the mitochondria, reduced capacity of the PCr/ATP shuttle system, and the 
background metabolic state. In addition, HF is a complicated pathology, with multiple 
factors that can promote this condition (i.e. ischemic and non-ischemic etiology) and 
potentially result in varied mitochondrial deficits. Indeed, as HF-related mitochondrial 
changes are currently unclear, the purpose of the second study of this dissertation was to 
evaluate mitochondrial respiration, mitochondrial content, and free radical levels in 
cardiac muscle from HF, with a special interest in the potential differences between 
patients with Ischemic HF (iHF) and Non-ischemic HF (niHF). We tested two hypotheses: 
First, mitochondria in cardiac muscle from patients with iHF would have lower OXPHOS 
than that of patients with niHF. Second, the mitochondria in cardiac muscle from patients 
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with iHF would exhibit a greater uncoupled respiration, and greater free radical levels as 
well as attenuated OXPHOS efficiency in comparison to patients with niHF. 
 
 
The role of the mitochondria in cardiac, skeletal, and  
vascular smooth muscle 
The integrated function of cardiac, skeletal, and the smooth muscle of the 
vasculature is essential for O2 delivery and utilization, especially, during exercise when 
synchronicity of these three muscle systems converge to help in determining functional 
capacity. The rhythmic contraction of cardiac muscle produces the driving force to 
convectively transport blood born O2 to the periphery where skeletal muscle utilizes the 
O2 for the metabolic requirements of locomotion [1, 38]. Blood vessels in the arterial 
system, relying on smooth muscle function, dictate the distribution of blood flow and O2 
transport, in response to O2 demand [39, 40]. In comparison to cardiac and skeletal 
muscle, smooth muscle has distinct characteristics in terms of structure, responses to 
stimuli, electrical coupling between fibers, and speed of contraction. Although vascular 
smooth muscle contains mitochondria, which produce ATP through cellular respiration to 
meet the energy requirements of this tissue, little is known about the respiratory capacity 
and function of these mitochondria.  
In cardiac muscle, mitochondria are the major metabolic organelles, taking up 35 % 
of a cells volume, and, at rest, producing almost 90% of ATP for cellular demands by β-
oxidation [33-36]. However, heart mitochondria are metabolically very flexible 
organelles, sometimes described as ‘metabolic omnivores’, performing equally well with 
pyruvate, ketone, and lactate as fuel sources, dependent only on their availability [41].  
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Interestingly, cardiac muscle mitochondria are not only ATP producing ‘powerhouses’, 
but are also associated with cardio-protection against ischemia-reperfusion injury, cell 
signaling, and cell death [42]. Therefore, mitochondria in cardiac muscle have been 
intensively studied in heart diseases such as HF [41, 43, 44]. However, most of these 
studies are limited to animal or diseased human hearts as obtaining samples from healthy 
human hearts is difficult. Future studies utilizing samples from healthy human hearts are 
therefore warranted to investigate the comprehensive function and role of mitochondria 
across the complete health and disease spectrum. 
In skeletal muscle, mitochondria are the primary controllers of cellular 
metabolism and signaling [45]. Typically 3-8% of skeletal muscle volume is 
mitochondria, with the variation being a consequence of skeletal muscle fiber type and 
adaptations to physical activity/inactivity [31, 46]. Mitochondrial ATP production is of 
great importance in skeletal muscle due to the high metabolic cost of locomotion and 
other forms of physical activity [47, 48]. Indeed, as indicated, skeletal muscle 
mitochondria adapt to different stimuli such as exercise and disease, resulting in a change 
in mitochondrial density and OXPHOS capacity [31, 46]. In fact, previous studies have 
suggested that a decline in skeletal muscle mitochondrial OXPHOS capacity and/or 
volume may contribute to muscle dysfunction [49-51]. Therefore, understanding and 
characterizing skeletal muscle mitochondrial function has significant implications in both 
health and disease. 
 Within blood vessels, both endothelial and smooth muscle cells contain 
mitochondria which produce ATP to maintain vascular tone, facilitate cellular transport, 
and power vascular cell secretion [15, 52]. These mitochondria typically comprise 3~5% 
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and ~5% of the smooth muscle and endothelial cell volume, respectively [53]. Recent 
evidence implicates vascular mitochondrial dysfunction in the development of vascular 
diseases [54-56]. Indeed, reductions in mitochondrial content and function have been 
linked to the age-related attenuation of vascular function [15], which warrants a 
comprehensive assessment of mitochondrial function in the blood vessels. As the 
comprehensive assessment of mitochondrial function in cardiac, skeletal, and smooth 
muscle has yet to be performed, the purpose of this third dissertation study was to 
determine the characteristics and respiratory function of mitochondria in cardiac, skeletal, 
and vascular smooth muscle. We tested two hypotheses: First, cardiac, skeletal, and 
vascular smooth muscles have distinct mitochondrial OXPHOS due to the different 
mitochondrial content. Second, intrinsic mitochondrial function would be different in 
cardiac, skeletal, and vascular smooth muscle. 
The integration of the cardiac, skeletal, and vascular smooth muscle plays an 
essential role in O2 transport and utilization. Therefore, a comprehensive understanding 
of these muscles, and the age- and disease-related alterations in both function and 
respiratory capacity, have important scientific and ultimately therapeutic implications. 
The overall purpose of this dissertation was to investigate the integrative function of the 
cardiac, skeletal, and vascular smooth muscle in terms of O2 transport and utilization with 
aging and disease by: 1) investigating the effects of aging on vasodilatory capacity and 
kinetics in human SMFAs, 2) determining the impact of HF etiology on mitochondrial 
function, content, and free radical levels, and 3) comprehensively examining and  
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The IMPACT OF AGE ON THE VASODILATORY FUNCTION OF  
 






Although advancing age is associated with attenuated skeletal muscle blood flow, 
and skeletal muscle feed arteries (SMFAs) have been recognized to play a regulatory role 
in the vasculature, little is known about the impact of age on the vasodilatory capacity of 
human SMFAs. Therefore, endothelium-dependent and -independent vasodilation was 
assessed in SMFAs (diameter 544±63 μm) obtained from 24, equally represented, young 
(33±2 yr) and old (71±2 yr) subjects in response to three stimuli 1) flow-induced shear 
stress, 2) acetylcholine (ACh), and 3) sodium nitropusside (SNP). Both assessments of 
endothelium-dependent vasodilation, flow (Young: 68±1; Old: 32±7 %) and ACh (Young: 
92±3; Old: 73±4 %), were significantly blunted (p<0.05) in the SMFAs of the old 
compared to the young, with no such age-related differences in endothelium-independent 
vasodilation (SNP). Furthermore, in response to an increase in flow-induced shear stress, 
vasodilation kinetics (Tau: Young: 55±1; Old: 92±7 s), and eNOS activation (Phospho-
eNOSs1177/total eNOS, Young: 1.0 ± 0.1; Old: 0.2±0.1) were also significantly attenuated 
in the old compared to the young (p<0.05). These findings reveal that the endothelium-
dependent vasodilatory capacity, including vasodilation kinetics, but not smooth muscle 
function, of human SMFAs is blunted with age. Given the regulatory role of SMFAs in 
skeletal muscle blood flow, these findings may explain, at least in part, the attenuated 





Attenuated cardiovascular function, as characterized by impaired oxygen delivery 
to skeletal muscle, is a well-documented phenomenon associated with aging (23, 30, 34) 
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and is likely responsible, at least in part, for the diminished exercise capacity in the 
elderly. Certainly,  with advancing age, due to a decrease in both maximum heart rate and 
stroke volume, maximum cardiac output is compromised (10, 30, 43).  Interestingly, not 
as a direct consequence, but in addition to this attenuated central cardiovascular response, 
many studies have also documented attenuated leg blood flow and vascular conductance 
during exercise in the old compared to the young (24, 28, 33, 35, 42). However, the exact 
location and mechanisms responsible for this diminished peripheral blood flow response 
is currently not well understood. 
In animals, it has been well documented that SMFAs, the inlets to the muscle bed 
upstream of the arterioles, due to location and vasoactive capacity, are primary blood 
flow regulators during physical activity (37, 44). Furthermore, additional animal work 
suggests that aging impairs endothelium-dependent dilation in SMFAs (45). Building 
upon these animal studies, Ives et al. (17, 19) recently translated these observations, using 
a pharmacological approach, providing evidence that human SMFAs also have the 
potential to regulate skeletal muscle perfusion. However, although the likely importance 
of human SMFAs has been highlighted, few such studies have been performed because 
these vessels are difficult to obtain and therefore little is currently known about the 
impact of age on SMFA vasomotor function. 
Utilizing in vitro methods to study animal skeletal muscle arterioles, which are 
downstream to the SMFAs, Muller-Delp et al. (29, 30) documented that local muscle 
blood flow was reduced in old rats, and proposed that the mechanism responsible for this 
age-related attenuation was impaired endothelium-dependent vasodilation. Additionally, 
Behnke et al. (2) recently revealed that the rate of skeletal muscle arteriole vasodilation, 
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likely reflective of the kinetics of muscle perfusion within the muscle, is blunted in old 
compared with young mice.  Therefore, in terms of the age-related reduction in oxygen 
delivery to skeletal muscle, these and other studies have identified a role for diminished 
nitric oxide (NO) bioavailability and, subsequently, endothelial-mediated vasodilatory 
capacity in skeletal muscle resistance arteries and arterioles in animal models (8, 14, 30). 
However, whether vascular dysfunction associated with advancing age, at the level of the 
SMFA in humans, contributes to the diminished peripheral blood flow associated with 
the elderly remains to be determined. 
 Consequently, utilizing pressure myography, this study sought to further examine 
the vasomotor function of human SMFAs with a specific focus on the impact of age. We 
tested three hypotheses: First, supporting the concept that SMFAs have regulatory 
potential, both young and old human SMFAs will exhibit significant vasodilatory 
capacity when stimulated by flow-induced shear stress, acetylcholine (ACh), and sodium 
nitroprusside (SNP). Second, the endothelium-mediated vasodilatory response, stimulated 
by flow-induced shear stress and ACh, will be attenuated in the old compared to the 
young, whereas the endothelium-independent vasodilatory response (SNP) will not be 
affected by age. Third, likely due to impaired endothelium-dependent vasodilation, the 
kinetics of flow-induced vasodilation will be slower in the old compared to young. If 
these hypotheses are proven to be correct, these findings will add to the understanding of 
skeletal muscle blood flow regulation with advancing age and have implications for the 
targeting of interventions aimed at maintaining physical function in the ever growing 







Subjects and general procedures 
 
 A total of 40 SMFAs from the axillary and inguinal regions were obtained from 
young (~33 yrs, n=20) and old (~71 yrs, n=20) subjects during melanoma-related 
surgeries. Twenty-four, equally represented, young and old SMFAs were used in all 
protocols except the Western blot analyses following only flow exposure which were 
performed in the 16 additional SMFAs (8 young and 8 old). All subjects were free from 
cancer and chemotherapy, but there were no other specific exclusion criteria for this 
study, although all medical conditions and medications were noted. All protocols were 
approved by the Institutional Review Board of the University of Utah and Salt Lake City 
VA Medical Center, carried out in accordance with the Declaration of Helsinki, and 
written informed consent was obtained from all subjects prior to surgery.  
 
 
Vessel harvest and preparation  
 
SMFAs (outer diameter ~500 μm, length 2-3.0 mm) from the axillary (e.g. 
serratus anterior or latissimus dorsi muscles) and inguinal (e.g. hip adductors or 
quadriceps femoris muscles) regions, obtained during sentinel node biopsy for melanoma 
surgery at the Huntsman Cancer Hospital and the Salt Lake City VA Medical Center, 
were studied. Patients were anaesthetized using a general protocol: propofol, fentanyl, 
benzodiazepines, and succinylcholine (32).  SMFAs were harvested after dissecting out 
sentinel lymph nodes for clinical analysis and were identified and classified based upon 
being a vascular inlet into a muscle bed, structure, coloration, and pulsatile bleed pattern 
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(18). SMFAs were ligated, excised, and immediately placed in iced normal physiological 
saline solution (PSS) prior to transfer to the laboratory within 15 min of harvesting (19). 
 
 
Vessel function protocols  
SMFAs from 24, equally represented, young and old subjects were assessed in 
these protocols. Initially, perivascular adipose and/or connective tissue around SMFAs 
was removed under a dissecting microscope (SZX10; Olympus, Center Valley, PA, USA) 
in cold (4 ◦C) PSS containing (mM): 145.0 NaCl, 4.7 KCL, 2.0 CaCl2, 1.17 MgSO4, 5.0 
glucose, 2.0 pyruvate, 0.02 EDTA, 3.0 MOPS buffer, and 1 g (100mL)-1 BSA at pH 7.4. 
Function of SMFAs was measured using pressure myography organ baths (110p; DMT 
Systems, Aarhus, Denmark). The arteries were cannulated at both ends with micropipette 
tips and the vessel outer diameters were recorded under an inverted microscope with a 
video camera (TS100; Nikon Eclipse, Melville, NY, USA), with data streamed in real 
time to edge detection software (DMT VAS v.2.0), monitored at a sampling rate of 1 kHz. 
Fluid leak was detected by pressurizing the vessel, with intraluminal pressure set at 60 
mmHg, closing the cannulas to the fluid reservoirs and assessing the capacity to maintain 
vessel diameter. Arteries free from leaks were then warmed to 37°C, allowed to develop 
spontaneous tone for a 30 min equilibration period (19), and then underwent vasodilation 
assessments and, ultimately, Western blot analysis.  
 
 
Vasodilation assessments  
 
Vasodilation (%) was assessed in response to three stimuli: First, to assess the 
endothelium-mediated vasodilatory response to flow-induced shear stress, intraluminal 
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flow was developed. This was achieved by altering the heights of the independent fluid 
reservoirs, contiguous with the SMFAs, in equal and opposite directions so that a 
pressure difference was developed across the vessel without altering mean intraluminal 
pressure (2). Pilot work revealed a large increase in % vasodilation in response to the 
flow induced by a pressure difference of 30 mmHg compared to 15 mmHg and more 
subtle increases in % vasodilation from 30 to 44 mmHg and 44 to 60 mmHg. Hence, a 
single pressure difference of 30 mmHg, which yielded an approximate flow rate of 30 
ul/min, was adopted for all subsequent flow experiments. With this flow rate and typical 
SMFA internal diameter, an expected shear rate of ~500 s-1 was calculated using the 
following equation: 8×mean velocity/vessel diameter (31). Second, to assess 
endothelium-dependent vasodilation pharmacologically, an ACh dose response curve 
(ACh, 10-7 to 10-3 M) was performed following pre-constriction with PE (10-6 to 10-4 M) 
to ~70% of the maximum PE response. Third, to assess endothelium-independent 
vasodilation, a SNP dose response curve was performed (10-9 to 10-4M) following pre-
constriction with PE (10-6 to 10-4 M) to ~70% of the maximum PE response. Vasodilation 
sensitivity was defined as the concentration of ACh or SNP that elicited 50% of the 
maximal response (EC50) which was calculated by a sigmoidal parameter, as described 
previously (18). Calcium free normal physiological saline solution was used to measure 
maximum passive relaxation of the feed arteries. 
 
Western blot analysis  
 
Baseline protein expression of phosphorylated eNOS at Serine 1177(p-eNOS ser1177, 
catalog no. 9570, Cell Signaling, Boston, MA), a well-described eNOS activation site (9), 
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and total eNOS (catalog no. 610296, BD Transduction, San Jose, CA) analysis was 
performed (47), using a subset (8 Young and 8 Old) of unused pieces of the same arteries 
which were assessed for vessel function. An additional 16 (8 Young and 8 Old) arteries 
were snap frozen in liquid nitrogen immediately after being exposed to only 6 min of 
flow at ~30 ± 1 ul/min to measure the impact of flow on eNOS and p-eNOS ser1177 protein 
expression. GAPDH (ab9485, Abcam, Cambridge, MA) was utilized as a loading control 
and therefore the protein data from the Western blot analyses were normalized GAPDH. 
The Western blots were performed in duplicate and the data averaged.  
 
 
Free radical measurement  
 
A subset (8 Young and 8 Old) of unused pieces of the same arteries which were 
assessed for vessel function were used in this protocol.  Electron paramagnetic resonance 
(EPR) spectroscopy was performed on frozen tissue to directly assess free radical 
concentration, utilizing  the superoxide specific spin probe 1-hydroxy-3-
methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine (CMH) (Enzo life sciences, Farmingdale, 
NY,USA), as previously described (4).  An EPR spectrometer (EMX X band, Bruker, 
Manning Park Billerica, MA) was utilized in combination with commercially available 
software (version 2.11, Bruker Win EPR System) to calculate the area under the curve of 




Percent vasodilation was used for data expression to account for baseline 




where Dt is the recorded diameter at a given time point, Dp is the diameter recorded after 
the addition of the vasoactive agent (i.e. pre-constriction diameter), and Di is the diameter 
recorded immediately before the addition of the vasoactive agent (initial diameter) (2).   
Vasodilation kinetics were determined by fitting the time-dependent vessel 
diameter changes during the shear stimulus period to a single exponential curve described 
by the following equation: 
Diametert=Diameterbase +Diameterend(1-e-(t-TD/ tau)) 
where Diametert is the change in diameter at time t, Diameterbase is the baseline diameter 
and Diameterend refers to the maximal vessel diameter in response to the shear stimulus, 
TD is the time delay before the onset of diameter change, and tau is the time constant to 





 Statistical analyses were performed using SPSS statistical software (SPSS 
version 17. SPSS, Chicago Il, USA). Group differences and vessel characteristics were 
compared using 2 way ANOVA. One-way repeated measures ANOVA were used to 
determine significant changes in vessel diameter for dose-responses to ACh and SNP. A 
student t- test was performed to identify the alteration in vessel diameter if the ANOVA 
was significant. For all analyses, a p-value of < 0.05 was considered significantly 









Subject characteristics  
 
A total of 40 subjects participated in this study, with 24 SMFAs harvested and 
assessed for vasodilatory function and basal eNOS and p-eNOS ser1177 protein expression 
and superoxide levels assessed in two subsets of 16 of these 24 vessels; Western blot 
analyses, following only flow exposure, was performed in the 16 additional SMFAs. In 
all assessments, the young and old were equally represented. The subject characteristics, 
obtained from preoperative examination medical records, are presented in Table 2.1. Note 
that users of cardiovascular (β-blocker, angiotensin- converting enzyme inhibitor, diuretic, 
Ca2+ channel blocker, etc.), diabetic (insulin, metformin, etc.), and cancer-related 
medications were excluded from the study. Also, it should be noted that all the blood 
chemistry and complete blood count results (Table 2.1) were within normal range, 





SMFAs were harvested from either the inguinal (n=27) and axial (n=13) regions 
and, in line with our previous observations (18, 19), there were no statistical differences 
in vasoconstriction or vasorelaxation responses in terms of anatomic origin or sex. Basal, 
unpressurized, outer diameter of the SMFAs was not statistically different between young 
and old (Young: 510 ± 12 um; Old: 514 ± 15 um). Additionally, maximal outer diameter 
of the SMFAs, achieved by Ca2+ free NPSS incubation, in young and old was not 





Vasodilatory response to intraluminal flow 
 
The PE-induced pre-constriction of the SMFAs prior to the flow stimulus was 
similar between groups (Old: 68 ± 5; Young 69 ± 4 %, P > 0.05). The greatest 
vasodilation in response to the intraluminal flow of 30 ± 1 ul/min was significantly 
reduced in the old compared to young (Old: 32 ± 7; Young 68 ± 1 %, P < 0.05) (Figures 
2.1 and 2.2). The Tau, an indicator of vasodilation kinetics, for the flow-induced 
vasodilation was significantly slower in the old compared to young (Old: 92 ± 7; Young: 
55 ± 13 s, P < 0.05). Additionally, the time delay before a statistically significant flow-
induced change in diameter occurred tended to be slower in the old compared to young 




Vasodilatory response to Ach and SNP 
 
The PE-induced pre-constriction of the SMFAs prior to the both the ACh and 
SNP vasodilatory stimuli were similar between groups (Old: 68 ± 5; Young 69 ± 5 %, P 
> 0.05). The SMFAs from the old exhibited significantly attenuated vasodilation in 
response to the highest dose of ACh (10-3 M), in the ACh dose response curve, than the 
young (Old: 73 ± 4; Young: 92 ± 3%, P < 0.05) (Figure 2.1 and 2.2A). In contrast, the 
greatest vasodilatory response to SNP (10-4 M), in the SNP dose response curve, was 
similar between old and young (Old: 112 ± 11 %; Young: 102 ± 4 %, P > 0.05) (Figures 
2.1 and 2.2B) . The sensitivity to ACh, assessed by log EC50, was significantly attenuated 
in the old compared to young (Old: -5.5 ± 0.3; Young: -4.1 ± 0.4, P < 0.05), whereas the 
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sensitivity to SNP was similar between old and young (Old: -5.75 ± 0.5; Young: -5.77 ± 
0.5, P > 0.05)(Figure 2.3). 
 
Protein expression 
The baseline ratio of p-eNOS ser1177/total eNOS was significantly greater in old 
compared to young (Old: 2.8 ± 0.08; Young: 1.0 ± 0.04 fold change, relative to young, P 
< 0.05) (Figure 2.4A). However, p-eNOS ser1177, an activation site of eNOS on the Serine 
1177 residue, to total eNOS protein expression in response to a 6 min flow stimulus was 
significantly lower in old compared to young (Old: 0.2 ± 0.08; Young: 1.0 ± 0.04 fold 
change, relative to young, P < 0.05) (Figure 2.4B). 
 
 
Free radicals  
 
The baseline EPR spectrospcopy signal for the CMH adduct, an index of 
superoxide concentration, was greater in old compared to young (Old: 3.9 ± 1.0: Young: 
1.7 ± 0.1 AUC / mg, P<0.05)(Figure 2.5). 
 
Discussion 
Although aging is associated with attenuated skeletal muscle blood flow and 
SMFAs have been recognized to play a regulatory role in the vasculature, little is known 
about the impact age on the vasodilatory capacity of human SMFAs. In this regard, there 
are several interesting and novel findings of this study. First, these data both confirm and 
extend the inference that human SMFAs are likely regulatory in nature. Specifically, the 
SMFAs are capable of significantly increasing vessel diameter in response to both 
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increased shear stress and pharmacological vasodilators, the magnitude of which, in vivo, 
would likely result in significant changes in vascular conductance. Second, the magnitude 
of the SMFAs endothelium-mediated vasodilatory capacity, assessed by the vasodilatory 
response to shear stress and ACh, is significantly attenuated with advancing age. 
However, in contrast, aging did not impact smooth muscle function. Third, in agreement 
with an age-related decrement in endothelium-mediated vascular function, shear-induced 
SMFA vasodilation kinetics are significantly attenuated with age. Finally, providing 
mechanistic insight into the age-related attenuation in SMFA vasodilatory function, 
shear-induced eNOS phosphorylation is significantly reduced with age, suggestive of a 
role for NO bioavailability in these findings. Given the potential impact of SMFAs in the 
regulation of blood flow during exercise, these findings may explain, at least in part, the 
attenuated perfusion of skeletal muscle with advancing age, which likely contributes to 
exercise intolerance in the elderly. 
 
 
Implication of attenuated SMFA vasodilation and vasodilation  
kinetics with age 
 
The regulation of oxygen delivery and therefore blood flow at rest and during 
exercise is an important component of homeostasis in both humans and animals (6, 19). 
In animals, it has been well documented that, in comparison to their younger counterparts, 
older animals exhibit an attenuated maximum vasodilatory capacity in skeletal muscle 
arterioles, which results in an impaired oxygen delivery to working muscles (29, 30). 
Furthermore, Behnke et al. (2, 3), using an isolated vessel approach, revealed an age-
related impairment in vasodilation kinetics. This would likely result in a temporal 
mismatch between oxygen delivery and oxygen consumption in skeletal muscle during 
29 
 
the rest to exercise transition, ultimately resulting in a low microvascular partial pressure 
of oxygen with advancing age. Although this age-related transient attenuation in 
microvascular oxygen availability has been documented to be a consequence of delayed 
blood flow to the muscle at the onset of contraction in animals (2), to our knowledge, 
until now, there had not even been a single study that examined the effect of age on 
human SMFA vasodilation kinetics, which may have the same downstream consequences. 
Indeed, this appears to be the first study demonstrating a reduced magnitude of 
vasodilation and vasodilation kinetics in human SMFAs as consequence of age (Figures 
2.1, 2.2, 2.3, and Table 2.1) and the impact on muscle oxygen availability still needs to be 
determined. 
Interestingly, at the onset of flow, the vasodilatory response of the current SMFAs, 
specifically the time to reach the peak diameter, was similar to previous studies 
examining other human vessels (5, 27), but significantly slower (~200 s) compared to the 
animal study performed by Behnke et al. (8-23 s) (2). The tau was also significantly 
slower in the human SMFAs compared to the animal arterioles (2). However, both the 
slower tau and the time to reach the peak shear-induced vasodilatory response in the 
human SMFAs may be due to the larger size of these vessels compared to the arterioles 
of much smaller animals (31). Another clear distinction between these vessels is location, 
with the SMFAs being external to the muscle while arterioles are internal. Thus, although 
both vessel types may have similar roles in terms of blood flow regulation, each may 
exhibit differing vasodilatory characteristics simply due to being a part of differing 
vascular beds (31). Of note, however, and in agreement with our previous studies (19), 
but certainly not a focus of the current work, there was no evidence of different SMFA 
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vasoactive responses as a consequence of anatomical location (i.e. axillary and inguinal 
regions). This implies that SMFAs from upper and lower limbs perform similarly in 
terms of vasodilation. 
Although it is currently not possible to quantify the exact physiological shear 
forces experienced by SMFA in humans, based upon studies in animals, Lipowsky et al. 
(25) suggested that an acceptable physiological shear rate for human arterioles would be 
in the 250-1500 s-1 range. Furthermore, Fisslthaler et al. (13) demonstrated that the 
induction of a shear stress of 12 dynes cm-2, equivalent to shear rate of 200 s-1, can 
significantly increase eNOS activation in cultured human umbilical vein endothelial cells. 
It should be noted that procedures in the current study resulted in a shear rate of ~500 s-1, 
which stimulated significant SMFA dilation. Interestingly, the delta pressure of ~30 
mmHg, employed in the current study, yielded a significantly greater vasodilatory 
response than the delta pressure of ~15 mmHg, while greater increases in pressure 
difference (∆~45 and ∆ ~60 mmHg), assessed in pilot studies, resulted in more subtle 
increases in vasodilation. These data could be interpreted to indicate that a shear rate of 
~500 s-1 is a physiologically relevant stimulus for human SMFAs, and advancing age 
blunts the vasodilatory response to such a level of shear. 
 
 
Potential mechanisms responsible for the age-related attenuation 
 in SMFA vasodilation 
 
Previous animal studies have suggested that there is an attenuated vascular 
conductance and a limited increase in red blood cell flux over time in muscle during 
dynamic exercise with advancing age (7, 15), indicative of compromised peripheral 
circulatory function (2, 7, 16). These prior studies, and other work focused upon the 
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impact of age on the microvasculature during exercise in animals, have revealed slower 
endothelium-dependent vasodilator dynamics in skeletal muscle arterioles, due to the 
reduced NO bioavailability in the old (2, 16, 30). In agreement with these studies, the 
current results extend these findings to human SMFAs, revealing that aging reduces flow-
induced (Figures 2.1 and 2.2) and ACh-induced (Figure 2.3) vasodilation, both indicators 
of endothelium-dependent dysfunction.  
Furthermore, this study revealed an attenuated increase in  p-eNOS ser1177 to total 
eNOS protein expression, a well-described activation site on eNOS (41),  in the SMFAs 
from the old subjects in response to an increase in shear stress, providing a mechanistic 
basis for the age-related attenuation in both the magnitude of vasodilation and 
vasodilation kinetics (Figure 2.4B). Interestingly, SMFAs from the old subjects also 
exhibited a significantly greater basal p-eNOS ser1177/Total eNOS protein expression 
compared to the young (Figure 2.4A) which contrasts with the predominant findings in 
the microvasculature of animals (40, 41, 47). However, these findings are well aligned 
with previous assessments of the vasculature in humans that have documented a greater 
activation of p-eNOS ser1177 with age at rest which was interpreted as an attempt to 
compensate for low NO bioavailibity (11, 36). Overall, these findings suggest that 
baseline eNOS activation is increased in the SMFAs of the old to compensate for the 
attenuated NO bioavailability; however, the SMFAs from the old appear less capable of 
activating eNOS in response to an increased shear stimulus compared to the young. 
Additionally, the EC50 for ACh, indicative of the sensitivity of muscarinic receptors in the 
endothelium, was reduced with age which may also play a role in the attenuated 
vasodilation kinetics in old.  
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It has been suggested that an increase in the production of reactive oxygen species 
(ROS) and/or limited antioxidant capacity with advancing age attenuates endothelial 
function in humans and animals (1, 30, 46). Interestingly, albeit in the basal state, the 
current study provides evidence of greater superoxide production in the SMFAs of the 
old compared to the young, as directly assessed by EPR spectroscopy (Figure 2.5). The 
reaction of NO with superoxide, to produce peroxynitrite (36), plays a major role in 
lowering NO bioavailibity, not only directly, but indirectly as peroxynitrite can uncouple 
eNOS. Indeed, Liu et al. (27) have documented that shear stress-induced ROS production 
in human coronary arteries decreases NO bioavailability, and others have documented 
that ROS impair NO-mediated vasodilation in the peripheral arteries with age (12, 26, 27, 
29). Furthermore, recent studies suggest that in the presence of blunted NO-mediated 
dilation, due to decreased NO bioavailability, compensatory vasodilatory mechanisms (i.e. 
H2O2) are favored in both old and diseased arteries (5, 22). This may be another potential 
explanation for the attenuated magnitude of flow-mediated vasodilation and the slowed 
vasodilation kinetics in the SMFAs of the old subjects. This potential compensatory 
mechanism, H2O2-mediated vasodilation, may not be as effective as NO in terms of either 
vasodilatory capacity or the speed of vasodilation; however, such speculation certainly 
needs further studies to confirm this contention. Regardless, the current study confirms 
that aging attenuates human SMFA vasodilatory capacity as well as vasodilation kinetics 
of human SMFAs and provides evidence that, mechanistically, this is likely due to 







The regulatory function of SMFAs 
 
Previous animal studies have suggested that SMFAs are capable of altering 
muscle blood flow by manipulating vascular conductance in accordance with metabolic 
requirements (21, 38). This vasoconstriction and vasodilation, previously documented in 
vitro, would likely translate into significant alterations in basal vascular resistance in vivo 
(37-39). Recent work by our group has provided translational evidence of the regulatory 
capability of human SMFAs, elicited by pharmacological stimulation, by documenting 
significant changes in calculated vascular conductance,  (19). In addition to these 
previous studies, and similar to that observed in a rodent model (20), the current study 
confirms and extends this evidence of the regulatory potential of human SMFAs by 
documenting vasodilation in response to a more physiologically relevant stimulus, an 
increase in shear stress. These findings suggest that SMFAs may be an important factor 
in regulating local blood flow at rest and during challenges to homeostasis such as 
exercise and orthostasis in humans. Importantly, this regulatory potential appears to be 
compromised with advancing age and this may have significant consequences in terms of 





This study utilized both a physiologically relevant flow-induced increase in shear 
stress and a pharmacologically-induced vasodilation to assess the impact of aging on 
vasodilatory capacity and vasodilation kinetics in human SMFAs. It was determined that 
the endothelium-dependent vasodilatory capacity and vasodilation kinetics, but not 
endothelial-independent smooth muscle function, of human SMFAs is blunted with age. 
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This attenuated endothelial-dependent vascular function seems to be explained by 
attenuated eNOS activation and subsequently NO bioavailability, and may be a 
consequence of elevated ROS production with age. Given the likely regulatory role of 
human SMFAs in skeletal muscle blood flow, these findings may explain, at least in part, 
the attenuated perfusion of skeletal muscle with advancing age which likely contributes 
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Table 2.1. Subject characteristics 
  Young (n=20) Old (n=20) 
Age (year) 33±2 71±2 * 
Male (male/total n) 17/20 18/20 
Female (female/total n) 3/20 2/20 
Height (cm) 174±2 169±9 
Body mass (kg) 79±10 72±8 
BMI (kg m-2) 26±4 25±5 
Systolic blood pressure (mmHg) 118.2±4.4 120.2±4.8 
Diastolic blood pressure (mmHg) 75.1±2.0 81.1±2.0 
Glucose (mg dl-1) 108.1±8.4 109.3±6.8 
Blood urea nitrogen (mg dl-1) 17.4±2.0 16.9±3.0 
Creatinine (mg dl-1) 0.8±0.2 0.9±0.1 
Albumin (g dl-1) 4.2±0.4 4.3±0.5 
Lactate dehydrogenase (U L-1) 501.4±34.3 504.3±36.1 
Hemoglobin (g dl-1) 14.4±0.9 13.5±0.8 
White blood Cells (thousands per microliter, K ul-1) 5.2±0.8 8.4±0.9 
Red blood Cells (millions per microliter, M ul-1) 4.5±0.3 4.2±0.2 
Platelets (K ul-1) 246.2±20.4 254±30.5 
Hematocrit (%) 42.8±1.9 40.3±1.3 
Lymphocytes (%) 30.4±4.0 32.4±2.0 
Monocytes (%) 8.0±1.6 7.8±1.3 
   Medications (Users/n) 
  Diuretics 0/12 0/12 
Angiotensin- converting enzyme inhibitors 0/12 0/12 
Diabetic drugs 0/12 0/12 
Statins 0/12 2/12 
Data are expressed as mean ± SE or number of subjects (out of the total number). * 




























Figure 2.1. Skeletal muscle feed artery peak % vasodilation induced by flow, 
acetylcholine (ACh), and sodium nitropruside (SNP) in young and old subjects. n = 
12 young and 12 old. Data are expressed as mean ± SE. * significantly different from the 













































Figure 2.2. Skeletal muscle feed artery vasodilatation kinetics illustrated as absolute 
change in diameter (A) and % vasodilation (B) in young and old subjects. n = 12 
young and 12 old. Data are expressed as mean ± SE. * significant difference between the 





























Figure 2.3. Skeletal muscle feed artery endothelial-dependent vasodilation, induced 
by increasing doses of acetylcholine (ACh) (A), and endothelial-independent 
vasodilation, induced by increasing doses of sodium nitropruside (SNP) (B) in young 
and old subjects. n = 12 young and 12 old. Data are expressed as mean ± SE. * 


























                                                                                
 
 
























Figure 2.4. Total eNOS and phosphorylated endothelial nitric oxide at Serine 1177 (p-
eNOS ser1177) in skeletal muscle feed arteries of young and old subjects in basal 
conditions (A) and the change induced by 6 min of flow inducing a shear rate of 
~500 s-1  (B). n = 8 young and 8 old in each panel. Data are expressed as mean ± SE. * 

















































































Figure 2.5. Basal superoxide level in young and old skeletal muscle feed arteries 
assessed by electron paramagnetic resonance (EPR) spectroscopy. EPR signal 
expressed as the area under the curve (AUC, arbitrary units). Representative spectroscopy 
signals inlayed. n = 8 young and 8 old. Data are expressed as mean ± SE. * significantly 










MITOCHONDRIAL FUNCTION IN HEART FAILURE: THE IMPACT OF  
 





 Although cardiac mitochondrial dysfunction is associated with heart failure (HF), 
this is a complex syndrome with two predominant etiologies, ischemic HF (iHF) and non-
ischemic HF (niHF), and the impact of mitochondrial dysfunction in these two distinct 
forms of HF is unknown. To determine the impact of HF etiology on mitochondrial 
function, respiration was measured in permeabilized cardiac muscle fibers from patients 
with iHF, niHF, and healthy donor hearts (HdH). Oxidative phosphorylation capacity 
(OXPHOS), assessed as Complex I, II, and I+II state 3 respiration, fell progressively 
from HdH to niHF, to iHF (Complex I+II: 54±1; 34±4; 27±3 pmol·s-1·mg-1) as did citrate 
synthase activity (CSA) (206±18; 129±6; 82±6 umol·g-1·min-1). Although still 
significantly lower than HdH, normalization of OXPHOS by CSA negated the difference 
in mass specific OXPHOS between iHF and niHF. Interestingly, Complex I state 2 
respiration increased progressively from HdH, to niHF, to iHF, whether or not 
normalized for CSA (23.2±3; 11±3; 6±2 pmol·mg-1·CSA), such that the respiratory 
control ratio (RCR) fell in the same manner across groups (5.3±0.2; 2.4±0.3; 1.3±0.2, 
P<0.05). Finally, both the total free radical concentration (60± 6; 46 ± 4 AU) and level of 
mitochondrial derived superoxide (1.0±0.2; 0.7±0.1 AU) were greater in iHF compared 
to niHF, respectively. Thus, the HF-related attenuation in OXPHOS actually appears to 
be independent of etiology when the lower mitochondrial content of iHF is taken into 
account. However, it is evidence of deleterious intrinsic mitochondrial changes in iHF, 
compared to niHF, including greater proton leak, attenuated OXPHOS efficiency, and 





 The heart is a vital organ with a high metabolic demand and is subsequently rich 
in mitochondria, with these energy producing organelles accounting for approximately 
35% of cardiac tissue volume (48) and generating up to 90% of the heart’s requirement 
for ATP (23, 31, 35). Due to an impaired energetic state, as evidenced by a reduction in 
the phosphocreatine to ATP ratio, the heart in HF has been described as an ‘engine 
without fuel’ and mitochondrial dysfunction has been implicated as an important 
component of this disease (29, 43). Such an attenuation in cardiac myocyte energy 
production may be the result of an alteration in the ratio of coupled, ATP producing, to 
uncoupled respiration, not ATP producing (2), potentially influencing the contractile 
capacity of the heart by creating a mismatch between energy supply and demand (48). 
However, previous studies focused upon HF and mitochondrial function have reported 
inconsistent results in terms of HF-related cellular adaptations including cell structure, 
mitochondrial substrate metabolism, and mitochondrial enzymes (11, 14, 32). These 
varied findings may, at least in part, be due to the differing impact of the multiple 
common co-morbidities associated with HF such as insulin resistance, diabetes, and the 
subsequently elevated lipid accumulation in cardiac tissue (7, 15) 
It is apparent that the exact impact of cardiomyopathy on mitochondrial function 
is not well characterized and may actually be further complicated by the fact that HF is a 
complex syndrome with two predominant etiologies, iHF and niHF. The first and most 
common, iHF, is coronary artery disease (CAD)-dependent, while niHF is not related to 
CAD and includes dilated cardiomyopathy, hypertrophic cardiomyopathy, and restrictive 
cardiomyopathy. Although perhaps blurred by common co-morbidities, it is somewhat 
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surprising that with such fundamentally different etiologies, it is still unclear if iHF and 
niHF differ in terms of cardiomyopathy-related cellular and non-cellular metabolic 
adaptations (47, 48) and mitochondrial free radical production (9, 47). Indeed, although 
several studies have speculated that CAD-induced chronic ischemia may have quite a 
different effect on cardiac mitochondrial function than non-ischemic tissue in the same 
heart (7, 48), the actual impact of HF etiology on mitochondrial function remains 
unknown. 
These unsolved issues regarding the impact of HF etiology are likely, at least in 
part, due to the limited opportunities to obtain human cardiac muscle, a failure to 
differentiate between HF etiologies, and may be further blurred by common co-
morbidities. Therefore, using normal HdH as a reference and without the inclusion of 
patients with Diabetes, to minimize the effect of this co-morbidity, this study sought to 
examine the impact of HF etiology on mitochondrial function. Specifically, a comparison 
of mitochondrial function in cardiac muscle from patients with iHF and niHF was 
performed to test the following hypotheses: First, mitochondria in cardiac muscle from 
patients with HF would exhibit significantly more attenuated OXPHOS than the HdH. 
Second, although, in mass-specific terms, cardiac muscle from the iHF would exhibit 
lower OXPHOS than from patients with niHF, this difference would be negated by 
normalizing for mitochondrial content. However, finally, it was additionally hypothesized 
that accompanying this reduced mitochondrial content in iHF would be evidence of 
greater uncoupled respiration, leading to attenuated OXPHOS efficiency and greater free 
radical production in comparison to patients with niHF. Recognizing that large-scale 
clinical trials have reported that iHF and niHF respond differently to interventional drug 
50 
 
therapies(8, 15), the assessment of potential differences in mitochondrial function due to 
etiology is important in terms of accurately targeting specific patients with the 







Cardiac tissue was collected from 35 patients with HF and 4 healthy donors. HF 
patients were classified as iHF (n=17, evidence of CAD) and niHF (n=18, no evidence of 
CAD, evidence of dilated cardiomyopathy, hypertrophic cardiomyopathy, or restrictive 
cardiomyopathy). Cardiac tissue from patients with iHF and niHF was harvested from the 
apex of left ventricle during either heart transplantation or left ventricular assist device 
(LVAD) implantation surgeries. All patients with HF were free from diabetes and there 
was no evidence of insulin resistance. The tissue from the HdH, not allocated for heart 
transplantation due to non-cardiac issues (e.g. heart size, incarceration, etc.) (36) was also 
harvested from the apex of left ventricle. Subjects or their legal representative (HdH) 
provided informed consent, and the study protocols were approved by the University of 
Utah and the Veteran’s Affairs Medical Center Institutional Review Boards. All protocols 
were carried out in accordance with the Declaration of Helsinki.   
 
    
Muscle fiber permeabilizing and mitochondrial respiration assessments 
 
  Following cardiac tissue collection, fat and connective tissue were removed from 
the cardiac muscle in pre cooled buffer A (in mM: 2.77 CaK2EGTA, 7.23 K2EGTA, 6.56 
MgCl2, 0.5 dithiothreitol (DTT), 50 K-MES, 20 imidazol, 20 taurine, 5.77 Na2ATP, 15 
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phosphocreatine, pH 7.1 at 4°C)  and the sample remained in this solution until 
permeabilization (36). 
All muscle samples were stored in precooled buffer A for no more than 30 min 
prior to the commencement of the permeabilizing procedures (25). Permeablizing 
procedures have been previously reported by our group (36). Briefly, muscle fibers were 
teased apart to increase permeability of the membrane and avoid limited diffusion of the 
substrates. After mild shaking for 30 min in buffer A with saponin (50 g/ml), the muscle 
was rinsed twice in buffer B (in mM: 2.77 CaK2EGTA, 7.23 K2EGTA, 6.56 MgCl2, 0.5 
DTT, 20 imidazole, 5.77 ATP, 15 PCr, 50 K-MES, 20 taurine, pH 7.0) for 10 min(36).  
Mitochondrial respiratory oxygen (O2) flux (JO2) was assessed by a Clark type, 
high resolution, respirometer (Oxygraph, Hansatech, Kings Lynn, UK). The 
permeabilized muscle fibers (2-4 mg wet wt) were incubated in the respirometer with 2 
ml of buffer B while being continuously stirred at 37°C. First, baseline muscle respiration 
was recorded, in the absence of respiratory substrates. To assess the function of each 
mitochondrial complex, O2 consumption was assessed using a series of respiratory 
substrates and inhibitors in the following order and final concentrations in the chamber: 
glutamate-malate (2:10 mM), ADP (5 mM), succinate (10 mM), cytochrome c (10 μM), 
rotenone (0.5 μM), antimycin-A (2.5 μM), oligomycin (2 μg/ml), N,N,N,N-tetramethyl- 
p-phenylenediamine (TMPD)-ascorbate (2:0.5 mM) (36). This allowed the determination 
of 1) Complex I state 2 respiration, the non-phosphorylating resting state that provides an 
index of proton leak, assessed in the presence of malate + glutamate, 2) Complex I, state 
3 respiration, the ADP-activated state of oxidative phosphorylation, assessed in the 
presence of glutamate + malate + ADP, 3) Complex I+II, state 3 respiration, assessed in 
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the presence of glutamate + malate + ADP + succinate  4) Complex II, state 3 respiration, 
assessed in the presence of glutamate + malate + ADP + succinate + rotenone 5) 
Complex IV respiration, assessed by the blocking of Complex 3 (antimycin A) and 
Complex V (oligomycin) followed by the addition of TMPD + ascorbate (36).  
 In each condition, respiration rate was recorded for 3-4 min and the average of the 
last 30 seconds was used for data analysis. Mitochondrial membrane integrity was 
evaluated by cytochrome c induction. The rate of O2 consumption was measured in pmol 
of O2 per second and then expressed relative to muscle sample mass (pmol·sec·wet 
weight). These respiration rates were further normalized by CS activity. The respiratory 
control ratio (RCR) was calculated as Complex I+II state 3/state 2 respiration. The 
substrate control ratio (SCR), an index of substrate utilization capacity at Complex II, 
was calculated as Complex I+II state 3/complex I state 3 (36).  
 
 
Biochemical and histochemical analyses 
 
Citrate synthase activity (CSA), an indicator of mitochondrial content (26), was 
measured by as previously described (26, 38). Briefly, the frozen cardiac muscle, that had 
been used for mitochondrial respiration measurements, was homogenized in extraction 
buffer (50 mM triethanolamine and 1 mM EDTA) using a bead homogenizer 
(BioSystems, Hamburg, Germany). CSA was assessed by spectrophotometry at 412 nm 
of the absorbance of light while incubated with 200 μl of reaction buffer (2 μm acetyl-
Coa, 200 μm 5,5’-dithiobis- (2-nitrobenzoic acid) (DTNB), 350 μM oxaloacetic acid, and 




Mitochondrial DNA (mtDNA) 
 The frozen cardiac muscle was homogenized and the DNA dissolved in 100 μl of 
Tris-EDTA. Five μl of a 50 times DNA dilution was used for PCR amplification with 
QuantiTect SYBR Green PCR Master Mix (Qiagen, Hilden, Germany) containing 0.5 
μM of each primer in a total volume of 25 μl. Levels of mtDNA and genomic DNA 
(gDNA), as determined by albumin content, was assessed by real-time PCR using a 
Biorad IQ real-time PCR machine (Stratagene, La Jolla, CA, USA), as previously 
described (41). The copy number of mtDNA and gDNA was used as an estimate of 
mitochondrial concentration in cardiac muscle  (24).  
 
 
Free radical measurements in cardiac muscle from iHF and niHF 
 
  Total free radical levels in the cardiac muscle from both the iHF and niHF 
patients was assessed by 2’-7’-dichlorofluorescein-diacetate (DCFDA) fluorescence. 
Tissue was homogenized in 0.05% Trypsin-EDTA (Invitrogen, Carlsbad, CA) using a 
motor-driven tissue homogenizer (Qiagen Inc., Valencia, CA) and incubated for 30 min 
at 37 ºC. Following centrifugation (5 min at 14,000 g), muscle lysates were incubated in 
5 mM DCF (invitrogen, Carlsbad, CA) dissolved in DMEM (Invitrogen, Carlsbad, CA) 
for 30 min at 37 ºC. Samples were centrifuged at 14,000 g for 5 min, pellets were re-
suspended in 200 μl lysis buffer (50 mmol/L Hepes, 150 mmol/L NaCl, 10% Glycerol, 
1% Triton X-100, 1.5 mmol/L MgCl2, 1 mmol/L, EGTA, 10 mmol/L Sodium 
Pyrophosphate, 100 mmol/L Sodium Fluoride and 100 μmol/L Sodium Vanadate, 1 
mmol/L PMSF, 10 μg/ml Aprotinin, and 10 μg/ml Leupeptin) and incubated for 10 min 
at 4º C under constant agitation. Samples were then centrifuged (14,000 g for 5 min) and 
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the supernatants transferred to a 96-well plate and fluorescence intensity was measured 
using a fluorescence plate reader (Biotek Instrument Inc, Winooski, USA). Data were 
normalized to protein content and the data were expressed as fold change (22). 
 To directly assess mitochondrial derived superoxide production, EPR 
spectroscopy (EMX X-band Bruker, Manning Park Billerica,  MA) was performed on 
frozen cardiac tissue samples from the patients with iHF and niHF, utilizing mitoTempo–





  One way ANOVA was performed using SPSS version 18 (SPSS Inc., Chicago, 
IL, USA) to detect differences in respiration, mitochondrial content, and reactive O2 
species production. If a significance difference was detected, a Tukey’s post hoc test was 
used to identify this difference. Correlations between CSA, Complex IV respiration, and 
mtDNA coppy number were assessed with a Pearson product moment correlation. For all 
analyses, a P value of <0.05 was considered significantly different. All data are expressed 






  The subject characteristics, disease conditions, and medications of the iHF and 
niHF patients are displayed in Table 3.1. The iHF and niHF patients were well-matched 
for age, physical, and blood chemistry characteristics. The 4 HdH came from 1 male and 
3 females with an average age of 52±3 yrs. Thus, the HdH were of a similar age as the 
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patients with iHF and niHF; however, other physical and blood chemistry characteristics 
were not available for these individuals. 
 
 
Oxidative phosphorylation capacity (OXPHOS) and mitochondrial content 
 
As illustrated in Figure 3.1, Complex I, Complex II, and Complex I+II state 3 
respiration rates (OXPHOS), expressed per unit of wet weight, was consistently 
attenuated in both the iHF and niHF compared to the HdH (P<0.05). However, OXPHOS 
was also consistently attenuated in the iHF compared to niHF (P<0.05) (Figure 3.1). 
Markers of mitochondrial content, CSA, Complex IV reparation, and mtDNA all fell 
consistently from HdH to niHF, to iHF (Figure 3.2) and these measures were 
significantly correlated with each other to varying extents (CSA vs mtDNA: r = 0.36, 
P<0.05; Complex IV respiration vs mtDNA: r = 0.42, P<0.05; CSA vs Complex 4 
respiration: r =0.8, P<0.05, Figure 3.3A). When mitochondrial Complex I, Complex II, 
and Complex I+II state 3 respiration were normalized by CSA, OXPHOS for the HdH 
remained significantly greater than both iHF and niHF, but the difference between iHF 
and niHF was negated (Figure 3.3B). Also, SCR, an index of Complex II substrate 
utilization capacity, was not different across iHF, niHF, and HdH (1.3± 0.1, 1.3±0.1, 
1.6±0.3, and P= 0.1, respectively). 
 
 
Non-phosphorylating respiration and RCR  
 
Complex I state 2 respiration, an index of non-phosphorylating proton leak, was 
significantly greater in iHF than niHF, but was still significantly greater in niHF than the 
HdH (P<0.05) (Figure 3.4A), and these differences were enhanced by normalizing for 
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CSA (Figure 3.4B). As both complex I state 2 respiration normalized by tissue wet 
weight and CSA fell from iHF to niHF to HdH (P<0.05), when the RCR (Complex I+II, 
state 3 respiration/Complex I, state 2 respiration) was calculated, there was a progressive 
and significant decline in RCR from HdH to niHF, to iHF  (P<0.05) (Figure 3.4C). 
 
 
Cardiac tissue free radical levels in iHF and niHF 
 
 The total free radical level, assessed by DCFDA fluorescence, was greater in iHF 
compared to niHF (Figure 3.5A). Similarly, the level of mitochondrial-specific 
superoxide, assessed by EPR spectroscopy, was significantly greater in iHF compared to 





The study sought to examine the impact of HF etiology on mitochondrial 
respiratory function and, to our knowledge, this is the first investigation to 
comprehensively assess these processes in both iHF and niHF, compared to HdH. 
Consequently, there are several novel findings of this study. First, expressed per mg of 
tissue, OXPHOS, assessed as Complex I, II, and I+II state 3 respiration and 
mitochondrial content, assessed by CSA, fell progressively from HdH to niHF, to iHF. 
Second, although still lower than HdH, normalization of OXPHOS by CSA negated the 
difference in mass-specific OXPHOS between iHF and niHF. Third, Complex I state 2 
respiration increased progressively from HdH to niHF, to iHF, such that RCR fell 
progressively from HdH to niHF, to iHF. Finally, measurements of both total free radical 
concentration and mitochondrial derived superoxide levels were significantly greater in 
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iHF compared to niHF. Thus, the HF-related attenuation in OXPHOS actually appears to 
be independent of etiology when the lower mitochondrial content of iHF is taken into 
account. However, this study also reveals deleterious intrinsic mitochondrial changes in 
iHF, compared to niHF, including greater proton leak, attenuated OXPHOS efficiency, 
and greater free radical levels. Identifying these etiology-specific mitochondrial function 




The impact of etiology on OXPHOS 
 
In the human heart, 90% of ATP is produced by OXPHOS; therefore, an 
attenuation of this process in HF constitutes a major concern in terms of cardiac energy 
production (13, 29, 33).  Indeed, the current study confirms and extends previous work 
that has typically observed attenuated Complex I state 3 respiration in both animal 
models of HF and patients with HF (42, 44, 45, 47). Specifically, this study documents a 
HF-related attenuation in OXPHOS, per mg of tissue, assessed as Complex I, Complex 
II, and Complex I+II state 3 respiration, falling progressively from HdH to niHF, to iHF. 
Therefore, although previous studies have suggested that mitochondrial structure and 
function is not affected by HF etiology (20, 21, 44), the current findings clearly 
demonstrate that tissue mass specific OXPHOS is attenuated with HF in general, but that 
this limitation occurs to a greater extent in iHF compared to niHF.  These conflicting 
results may be a consequence of the inclusion of co-morbidities such as diabetes and 
insulin resistance in prior studies, in contrast the current study excluded these 
confounding factors. Interestingly, when mass-specific OXPHOS was normalized by 
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CSA, a marker of mitochondrial content, considered valid in HF (19, 26, 27, 36), the 
differences in respiration between iHF and niHF were negated. This suggests that 
OXPHOS per unit of mitochondrial content is similar between iHF and niHF and the 
observed differences in respiration were due to differences in the quantity rather than the 
quality of mitochondria between etiologies, with iHF exhibiting lower mitochondrial 
content and therefore lower mass-specific OXPHOS. 
Utilizing the innovative approach of examining mitochondrial respiration in 
cardiac tissue from ischemic and non-ischemic areas of the same heart, Stride et al. (47), 
inferred that iHF likely resulted in a mitochondrial defect that manifests predominantly at 
Complex II. However, the current findings suggest that the attenuated OXPHOS with HF, 
including complex II respiration, is attenuated as a consequence of lower mitochondrial 
content, and, therefore, this apparently limited function was no longer evident when 
respiration was normalized for CSA (Figure 3.3B). Additionally, in the current study, 
SCR, an index of substrate utilization capacity at Complex II, was similar between iHF 
and niHF, further supporting the conclusion that Complex II function is not specifically 
impacted by HF etiology.  
 
 
Mitochondrial content in iHF and niHF 
 
  Interestingly, there is little accord as to the most appropriate and valid method to 
assess tissue mitochondrial content; however, suggested approaches include electron 
microscopy, CSA, mtDNA, and Complex IV respiration.  Recently, by revealing a strong 
relationship between CSA, a reasonably well-accepted method, and Complex IV 
respiration, in healthy cardiac, skeletal, and vascular smooth muscle, our group 
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concluded that Complex IV respiration is an acceptable marker of mitochondrial content 
(26, 36). The current data extend this previous conclusion to diseased tissue because 
across HdH, niHF, and iHG, complex IV was again highly correlated with CSA (Figure 
3.3A). Additionally, mtDNA copy number revealed a similar pattern of reduction from 
HdH to niHF, to iHG as did CSA and Complex IV respiration (Figure 3.2). However, 
upon closer inspection, it was apparent that by far the best agreement amongst these 
measures of mitochondrial content was between CSA and Complex  IV respiration 
(Figure 3.3A), adding a degree of construct validity to both indices. In terms of HF, these 
findings of diminished mitochondrial content are well aligned with a previous study by 
Lemiex et al., (27) which reported a decrement in Complex IV enzyme activity in cardiac 
tissue from patients with HF compared to healthy controls. Therefore, in combination 
with prior work, the current findings suggest that both CSA and Complex IV respiration 
are viable markers of mitochondrial content in both healthy and diseased cardiac muscle.  
Perhaps, mechanistically, as a result of diminished mitochondrial calcium 
handling capacity, the activation of caspase-3, and the triggering of apoptosis (37, 53), 
several studies have reported a reduction in mitochondrial content in the cardiac tissue of 
patients with end-stage HF (Class IV). However, the specific impact of HF etiology on 
mitochondrial content has not been investigated (17, 21, 30, 40). As already noted, 
recently, Stride et al. (47) investigated the impact of ischemia on mitochondrial content 
by examining ischemic and non-ischemic regions within the same heart. The authors 
determined that, in comparison to well-perfused regions of the heart, mitochondrial 
content was reduced in the chronically ischemic areas, implicating a link between chronic 
ischemia and reduced mitochondrial content (47). The current study supports this 
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contention by clearly revealing distinct etiology-dependent differences in mitochondrial 
content between iHF and niHF, with iHF resulting in reduced mitochondrial density 
(Figure. 3.2). The specific mechanism underlying the reduced mitochondrial content in 
iHF compared to niHF remains unclear; however, this finding is likely related to the 
impaired tissue oxygenation associated with chronic ischemia. This could result in 
chronic low–grade inflammation, the up-regulation of the pro-inflammatory cytokine 
tumor necrosis factor-α, and attenuated mitochondrial biogenesis, as evidenced by 
reduced PGC-1α (16, 34). Additionally, impaired mitochondrial oxygenation attenuates 
respiratory complex function and adenine nucleotide translocase which may lead to 
membrane dysfunction and, eventually, cell death (52).  Another, outcome of chronic 
ischemia is the accumulation of collagen and the development of fibrosis, reducing 
mitochondrial density per tissue mass, a phenomenon which has been documented to be 
more prevalent in iHF than niHF (28, 39). Each of these factors deserve further attention 
to determine the mechanism responsible for the observed reduction in mitochondrial 
content in iHF compared to niHF  
 
 
Non-phosphorylating respiration and RCR in iHF and niHF 
 
The proton motive force, the proton gradient between the matrix and the 
intermembrane space of the mitochondria, facilitates ATP production (49) and in 
combination with non-phosphorylating proton conductance regulates the kinetics and 
efficiency of mitochondrial respiration (2, 36). Interestingly, in the current study, despite 
greater mitochondrial content in niHF compared to iHF, tissue mass-specific Complex I 
state 2 respiration, an indicator of proton leak, was greater in iHF compared to niHF 
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(Figure 3.4A). Therefore, when normalized for CSA, this elevated Complex I state 2 
respiration in the iHF compared niHF was not only maintained, but was exaggerated, 
confirming that proton leak per mitochondrial content was greater in iHF compared to 
niHF. This general finding, of greater proton leak in HF, is well-aligned with previous 
studies suggesting greater mitochondrial uncoupling with mitochondrial membrane 
damage and subsequent reductions in ATP production in mice with HF (1, 2, 52). 
Furthermore, the current etiology specific findings suggest that chronic ischemia 
increases mitochondrial H+ ion membrane permeability that likely contributes to 
mitochondrial dysfunction. This difference in proton leak may be a fundamental 
difference which characterizes HF etiologies (4, 5) (Figure 3.4A and 3.4B). Additionally, 
the RCR, the ratio of Complex I+II state 3 to Complex I state 2 respiration, provides an 
index of mitochondrial dysfunction, with a low RCR reflecting defects that lead to 
OXPHOS inefficiency (3, 36). The current findings reveal a significantly lower RCR in 
iHF compared to niHF. This attenuated RCR in iHF compared to niHF provides 
additional novel evidence that HF etiology results in physiologically significant 
alterations in mitochondrial proton leak. Therefore, this study reveals that iHF exhibits an 
even greater attenuation in OXPHOS efficiency than niHF and this is predominantly due 
to distinct etiology-dependent uncoupled respiration. 
 
   
Etiology specific free radical production in iHF and niHF 
 
Previous studies have reported elevated free radicals in HF (6, 48); however, the 
source of these free radicals, mitochondrial or non-mitochondrial, is not clear. 
Additionally, these previous investigations are somewhat confounded by the use of acute 
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ischemia, in animal models, to induce free radical production (6, 48). The current study 
utilized DCFDA to assess basal free radical levels in cardiac muscle from patients with 
iHF and niHF and revealed a greater total free radical level in the tissue from the patients 
with iHF (Figure 3.5A). Furthermore, the direct assessment of mitochondrial derived 
superoxide levels, utilizing the mitoTempo-H spin probe and EPR spectroscopy, revealed 
greater free radical levels in iHF compared to niHF (Figure 3.5B). Although speculative, 
it is tempting to imply that this may be a consequence of both a reduction in 
mitochondrial content and increased H+ membrane permeability in iHF compared to 
niHF (34, 51).  
Previously, Stride et al. (47) measured greater free radical production in ischemic 
compared to non-ischemic regions of the same heart in patients with HF. In agreement 
with this study, the current findings suggest that chronic ischemia may be an important 
factor contributing to increased mitochondrial-derived free radical production in iHF. 
Potential mechanisms responsible for this augmented free radical production include 
attenuated Complex III function and diminished coenzyme Q binding protein (COQ10), 
both of which would result in a “bottleneck” for electron transport through the respiratory 
chain, allowing more time for free radical production (47, 48). However, it is still 
somewhat controversial as to whether increased proton leak decreases free radical 
production due to decreased proton motive force and the subsequent attenuation of the 
coupled oxidative phosphorylation or if an increased proton leak reduces ATP/O2 ratio 
(P/O ratio), leading to an increase free radical production due to a decreased integrity of 
mitochondrial membranes (46, 50).  In actuality, the relationship between proton motive 
force and free radical formation is likely described by a U-shaped curve and thus it will 
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not be possible to discern a single, simple, answer to this complex issue (10). 
Nonetheless, this study has identified a greater total and mitochondrial-derived free 
radical production in the cardiac muscle of patients with iHF compared to niHF, 




The HF-related attenuation in OXPHOS appears to be independent of etiology 
when the lower mitochondrial content of iHF, compared to niHF, is taken into account. 
However, there are also deleterious intrinsic mitochondrial changes in iHF, compared to 
niHF, including greater proton leak, attenuated OXPHOS efficiency, and greater free 
radical levels. Identifying these etiology-specific mitochondrial function differences is 
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Table 3.1. Characteristic of the ischemic and non-ischemic heart failure (HF) patients  
               
   Ischemic HF 
(n=17) 
   Non- ischemic HF 
 (n=18) 
Age (years)  57 ± 3 53 ± 4 




Systolic blood pressure (mm Hg) 115±3 112±4 
Diastolic blood pressure (mm Hg) 74±2 72±3 




Type 2 diabetes 
















































WBC (K uL)  8.9±0.2 7.7±0.4 
BMI: body mass index; NYHA: New York Heart Association; LVEF: left ventricular 
ejection fraction; Type II DM: type II diabetes mellitus; ACE inhibitor: angiotensin 
converting enzyme inhibitor; HDL: high-density lipoprotein; LDL: low-density 






Figure 3.1. Oxidative phosphorylation capacity assessed as Complex I, Complex II, and 
Complex I+II state 3 respiration in the cardiac muscle of healthy hearts and patients with 
ishchemic and non-ischemic heart failure (HF). JO2, O2 flux. * Significantly different 
from healthy hearts, P<0.05; † Significantly different from non-ischemic HF, P<0.05. 















Figure 3.2. Markers of mitochondrial content in cardiac muscle from healthy hearts, and 
patients with ischemic and non-ischemic heart failure (HF). A: Citrate synthase activity, 
B: mitochondrial DNA copy number, and C: Complex IV respiration. JO2, O2 flux. * 
Significantly different from healthy hearts, P<0.05; † Significantly different from non-
ischemic HF, P<0.05; mtDNA, mitochondrial  deoxyribonucleic acid. Data presented as 














Figure 3.3. The significant relationship between citrate synthase activity (CSA) and 
Complex IV respiration (A) and oxidative phosphorylation capacity normalized by CSA 
(B) in cardiac muscle from healthy hearts and patients with ischemic and non-ischemic 
heart failure (HF). * Significantly different from the healthy hearts, P<0.05. Healthy 
hearts, triangles; non-ischemic HF, circles; ischemic HF, squares. Data presented as mean 




Figure 3.4. Uncoupled mitochondrial respiration (complex I state 2) normalized by tissue 
wet weight (A) and then by citrate synthase activity (B), and respiratory control ratio 
(RCR, complex I+II state 3 / complex I state 2 respiration) (C) in cardiac muscle from 
healthy hearts and patients with ischemic and non-ischemic heart failure (HF). * 
Significantly different from healthy hearts, P<0.05; † Significantly different from non-





Figure 3.5. Basal free radical levels in cardiac muscle from patients with ischemic heart 
failure (HF) and non-ischemic HF. A: Total free radicals measured with, 2’-7’ 
dichlorofluorecein diacetae (DCFDA) fluorescence in whole-tissue extract. Data 
presented as fold change relative to Ischemic HF. B: Mitochondrial-derived superoxide 
levels measured in frozen cardiac muscle utilizing the mitoTempo-H spin probe and 
electron paramagnetic resonance spectroscopy. * Significantly different from non-
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The overall purpose of this dissertation was to investigate the integration of 
cardiac, skeletal, and vascular smooth muscle function in terms of O2 transport and 
utilization with aging and disease. Specifically, the impact of aging and disease on both 
function and respiratory capacity were evaluated in human muscle tissue samples 
utilizing in vitro approaches.  
With the goal to better understand the age-associated reduction in vascular 
function in old individuals, the first study of this dissertation examined vasomotor 
function in human SMFAs, utilizing pressure myography. Initially, we further determined 
that SMFAs likely contribute to the regulation of vascular resistance/conductance in vivo 
by documenting vasodilation in response to a physiologically relevant increase in shear 
stress. In terms of aging, this study revealed reduced endothelial function in the elderly, 
which was identified by attenuated vasodilation kinetics in old SMFAs compared to 
young. Additionally, maximal endothelium-mediated vasodilatory capacity in response to 
physiological stimuli, increased shear stress, and pharmacological stimuli, Ach dose 
response, was significantly reduced. These findings suggest that the attenuated 
endothelial function observed with aging in human SMFAs may be a contributing factor 
to impaired O2 delivery capacity with advancing age. Also, the attenuated vascular 
function with age was associated with a reduced shear-induced activation of eNOS, and 
elevated ROS production in human SMFAs. Therefore, the present study has identified 
blunted endothelial function and elevated free radicals in human SMFAs with age and 
these deleterious changes may contribute to the exercise intolerance commonly observed 
with advancing aging age, by diminishing O2 transport. 
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The second study of this dissertation sought to examine the impact of HF etiology 
on mitochondrial function in HF. Specifically, cardiac muscle tissue mitochondrial 
function and free radical levels were evaluated in cardiac muscle from patients with iHF 
and niHF in comparison to those from healthy donors hearts (HdH). Both mitochondrial 
quality and quantity were compromised in HF compared to HdH. Interestingly, however, 
tissue mass-specific OXPHOS was even lower in iHF compared to niHF but 
mitochondrial content was also significantly lower in iHF compared to niHF. Thus, when 
tissue mass-specific OXPHOS capacity was normalized for mitochondrial content, the 
difference in tissue mass-specific OXPHOS between iHF and niHF was negated. 
Interestingly, iHF exhibited greater non-phosphorylating respiration, and a lower 
OXPHOS efficiency compared to niHF. Furthermore, total free radical levels and 
mitochondrial-derived superoxide levels were elevated in iHF compared to niHF. 
Collectively, these data suggest an etiology-specific reduction in intrinsic mitochondrial 
function. Therefore, the second study of this dissertation has identified that HF etiology 
plays an important role in the mitochondrial dysfunction in HF. These findings suggest 
that therapeutically targeting mitochondrial content, as well as mitochondrial free radical 
production, potentially in an etiology- specific manner, could result in progress in treating 
patients with HF.  
The third study of this dissertation examined the characteristics and respiratory 
function of mitochondria in cardiac, skeletal, and vascular smooth muscle by assessing 
mitochondrial respiration in the smooth muscle of human SMFAs, in comparison to that 
of cardiac and skeletal muscle. This study documented the ability to successfully measure 
vascular smooth muscle mitochondrial respiration using the permeablized fiber approach 
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routinely used with both cardiac and skeletal muscles. Within the tissue types, tissue 
mass-specific mitochondrial OXPHOS fell from cardiac to skeletal, to smooth muscle. 
Also, mitochondrial content as assessed by citrate synthase activity (CSA), fell 
progressively from cardiac, to skeletal, to smooth muscle. Therefore, when this tissue 
mass-specific OXPHOS was normalized by CSA, the differences in OXPHOS capacity 
were no longer apparent. Interestingly, there were significant muscle-specific differences 
in both non-phosphorylating respiration and the OXPHOS efficiency. These findings 
document that different muscle types have distinct intrinsic mitochondrial function, 
which appear to affect the OXPHOS efficiency and therefore may potentially impact free 
radical production.  
In summary, this research examined the integration of cardiac, skeletal, and vessel 
smooth muscle in O2 transport and utilization with aging and disease. Specifically, this 
dissertation research has identified that aging and disease attenuate O2 transport and 
utilization by adversely impacting vascular endothelial and mitochondrial function, which 
are both associated with elevated oxidative stress. Importantly, these maladaptations may 
be therapeutic targets for improving impaired O2 transport and utilization with aging and 
disease. Therefore, by studying the components and integrative function of these three 
muscle systems, this research may contribute significantly to our understanding of the 
limitations to O2 transport and utilization with aging and disease. Collectively, the 
conclusions gathered from this dissertation provide mechanistic insight which may be 
utilized to improve functional capacity with aging and disease, and therefore potentially 
enhance the quality of life in old and diseased populations.  
 
